Anebulo Pharmaceuticals (NASDAQ:ANEB) Issues Quarterly Earnings Results

Anebulo Pharmaceuticals (NASDAQ:ANEB) posted its quarterly earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Stock Performance

Shares of NASDAQ:ANEB opened at $1.96 on Friday. Anebulo Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $3.61. The stock has a market capitalization of $50.83 million, a P/E ratio of -5.30 and a beta of -1.01. The stock has a 50-day simple moving average of $2.05 and a 200-day simple moving average of $2.35.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.